Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

doi:10.3748/wjg.v22.i48.10512

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 48

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (26516)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

2562

WORD

349

HTML

20377

Figures (1-4)

314

Sum=23602

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1212

Download

1702

Sum=2914

Dec 28, 2016 (publication date) through Nov 15, 2024

Times Cited of This Article

Times Cited (420)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Dec 28, 2016; 22(48): 10512-10522
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10512

Full Size Figure Download Figure

Figure 4 Mechanism of action of three potential therapeutic drugs-ursolic acid, 24-nor-ursodeoxycholic acid, and resveratrol-for treating fibrosis.

Citation: Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 2016; 22(48): 10512-10522
URL: https://www.wjgnet.com/1007-9327/full/v22/i48/10512.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i48.10512